Switzerland· 57442009
Alfuzosin Sandoz 10 mg, Retardtabletten
A alfuzosin product, registered in Switzerland by Sandoz Pharmaceuticals AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Alfuzosin is registered in 18 of 19 countries.
Countries holding a registration under ATC G04CA01 (alfuzosin), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 11 of them publish a price we can compare per daily dose
Alfuzosin · ATC G04CA01
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alfuzosin costs, country by country.
Normalised to the WHO defined daily dose (7.5 mg), the median price runs from $0.25 in France to $0.93 in Switzerland — a ×3.7 gap.
- Switzerland: $0.93 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Alfuzosin · price per daily dose (7.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.93
- ES Spain$0.34
- IT Italy$0.25
- FR France$0.25
The record
At a glance
Swissmedic (Switzerland)- Manufacturer
- Sandoz Pharmaceuticals AG
- Country
- Switzerland (CH)
- ATC code
- G04CA01
- ATC class
- Alfuzosin
- Defined daily dose
- 7.5 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- July 9, 2026
Packs & prices · 1
1 priced- gtin768057442009630 StkCHF 30.7
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
330 interactions on record for alfuzosin.
Graded by severity as the source publishes them — 47 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alfuzosin · interactions on record
330 records
- 47 severe
- 182 moderate
- 3 minor
- 48 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
50 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under G04CA01
Alfuzosin, as other registers publish it.
- PolandAlfabaxRanbaxy (Poland) Sp. z o.o.
- IrelandAlfu 10 mg Prolonged-release TabletsAurobindo Pharma (Malta) Limited
- FinlandAlfuranRanbaxy (UK) Limited
- PolandAlfurionOrion Corporation
- GermanyAlfuzosinAuxilto Healthcare Gmbh
- CanadaALFUZOSINSIVEM PHARMACEUTICALS ULC
- CanadaALFUZOSINSANIS HEALTH INC
- DenmarkAlfuzosin "Orion"Orion Corporation
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dd93e5a5-fa1b-4712-947e-3c85f6a707c6 GET /v1/drugs/dd93e5a5-fa1b-4712-947e-3c85f6a707c6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "alfuzosini hydrochloridum 10 mg",
"valid_from": "2006-05-01",
"limitations": null,
"galenic_form": "Ret Tabl 10 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2006-05-01",
"self_retention_pct": 10
}See everything about alfuzosin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.